- Michael Aschner, Albert Einstein College of Medicine
- Phil Biggin, University of Oxford
- Lucio Guido Costa, University of Washington
- David H Farb, Boston University School of Medicine
- Giorgio Palu, University of Padova
- Christopher Morrey, BioMed Central
An in vitro study suggests that combination of low-dose cytarabine, all-trans retinoic acid and valproic acid has immunomodulatory effects that differ between T cell subsets and may affect other immunocompetent cells through the altered release of soluble mediators.
A cross-sectional study suggests that initiation of saxagliptin therapy was associated with prior poor glycemic control, prior oral anti-diabetic drugs use, diagnoses of hypertension and hyperlipidemia.
An in vivo study suggests that respiratory acidosis and alkalosis may blunt albuterol responsiveness in the airway wall but further investigation is required to determine whether the effect is driven by intracellular or extracellular pH or pCO2.
Marta Sidoryk-Wegrzynowicz and Michael AschnerBMC Pharmacology and Toxicology 2013, 14:23 (18 April 2013)
BMC Pharmacology and Toxicology 2015, 16:17
News from the web
- 03 July 2015
- Viral protein in their sights
- 02 July 2015
- Testosterone therapy: the hormone debate rages on
- 30 June 2015
- Using bacterial 'fight clubs' to find new drugs
BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials.
BMC Pharmacology and Toxicology is part of the BMC series which publishes subject-specific journals focused on the needs of individual research communities across all areas of biology and medicine. We offer an efficient, fair and friendly peer review service, and are committed to publishing all sound science, provided that there is some advance in knowledge presented by the work.
BMC series - open, inclusive and trusted.
Section Editor's profile
David H Farb is Professor and Chair of the Department of Pharmacology and Experimental Therapeutics at Boston University School of Medicine. He is Principal Investigator and Director of the Laboratory of Molecular Neurobiology and Director of the university-wide NIGMS training program in Biomolecular Pharmacology. A renowned neuropharmacologist, his research integrates existing electrophysiological, behavioral, pharmacological, and molecular genetic technologies in a novel systems-level platform to establish a molecular dissection of spatial memory. Dr Farb is Section Editor for 'Basic pharmacology' and you can read more about the key issues in this field and his aspirations for the journal in his recent interview here.
"Pharmacology is a powerful interdisciplinary science providing an essential link between hypotheses developed from molecular, systems, and clinical models with the ultimate goal of improving human health. Our journal publishes timely research describing advances in a broad range of disciplines that combine novel approaches within a framework of rigorous scientific research."
BMC series blog
- 03 July 2015
- Seafaring spiders set sail for distant shores
- 29 June 2015
- Stunting: a rarely discussed public health problem
- 26 June 2015
- Metropolitan Metagenomics
BMC Pharmacology and Toxicology assimilated the Editorial boards and history of BMC Pharmacology and BMC Clinical Pharmacology on fusion of the journals in 2012. The full archive of BMC Pharmacology is available from its own archive website, and the objectives and aspirations of the merged journal are explained in the editorial that accompanied the fusion. The full archive of BMC Clinical Pharmacology is available here.